Fermenta Biotech Ltd.
NSE: FERMENTA · Pharmaceuticals · sector
₹447.05NSE close 2026-10-26
Key numbers
Market cap₹1,282 cr
Price₹447.05
52w high / low₹583 / ₹249
P/E–Sector median 27.9x
P/B–Sector median 2.9x
Book value₹–
Dividend yield–Sector median 0.48%
ROE–Sector median 11.7%
ROCE–Sector median 12.3%
OPM–Sector median 14.0%
Debt / equity–Sector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover–
Current ratio–
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Price ₹447.05 on 2026-10-26: -23.3% from the 52-week high, +79.6% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹553.25 · low ₹235.65
RevenueNet profit
Quarterly results
| ₹ cr | Jun 2026 |
|---|---|
| Revenue | 122 |
| EBITDA | 18 |
| OPM % | 14.8% |
| Other income | 4 |
| Net profit | 10 |
| EPS (₹) | 3.40 |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | TTM |
|---|---|
| Revenue | – |
| EBITDA | – |
| Net profit | – |
| EPS (₹) | – |
| Dividend / share (₹) |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 60.12% |
| FIIs | 1.05% |
| DIIs | 0.00% |
| of which Mutual funds | 0.00% |
| of which Insurance | 0.00% |
| Government | 0.00% |
| Public (non-institutions) | 36.43% |
| Quarter | Aug 2026 | Sep 2026 |
|---|---|---|
| Promoters % | 64.09% | 60.12% |
| Promoter group | % |
|---|---|
| Krishna Datla | 36.04% |
| Satish Varma Azad Nadimpally | 11.73% |
| Anupama Datla Desai | 8.70% |
| Preeti Thakkar | 3.65% |
| Public holders above 1% | % |
|---|---|
| Fermenta Biotech Limited Esop Trust | 2.39% |
| Rakesh Kantilal Shah | 1.72% |
| Anant Jain | 1.53% |
| Krishan Premnarayen . | 1.38% |
16,084 shareholders. Pledged: – of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| FERMENTA | ₹1,282 cr | – | – | – | – | – | – | – |
Business segments (2026-06-30)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Bulk drugs/chemicals | ₹117 cr | 93.0% | ₹19 cr | 16.2% |
| Unallocated | ₹7 cr | 5.4% | ₹-2 cr | -27.7% |
| Property (Refer Note 4) | ₹2 cr | 1.6% | ₹0 cr | 3.4% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-08-05 | Dividend | Dividend - Rs 3.75 Per Share |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | FERMENTA |
| BSE code | 506414 |
| ISIN | INE225B01021 |
| Face value | ₹5.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.